Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
11 hedge funds and large institutions have $476K invested in Rosetta Genomics Ltd. in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
51% more capital invested
Capital invested by funds: $316K → $476K (+$160K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
25% more call options, than puts
Call options by funds: $15K | Put options by funds: $12K
10% more funds holding
Funds holding: 10 → 11 (+1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$99.8K |
| 2 |
SIM
Spark Investment Management
New York
|
+$95.2K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$66.9K |
| 4 |
Morgan Stanley
New York
|
+$29.1K |
| 5 |
WA
WFG Advisors
Dallas,
Texas
|
+$1.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$45K |
| 2 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$44K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$11.6K |
| 4 |
U
UBS
Zurich,
Switzerland
|
-$8.78K |
| 5 |
Citigroup
New York
|
-$3.19K |
ROSG Hedge Fund Activity: Q4 2013 in Review
11 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q4 2013, worth a combined $476K — up 51% from $316K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ROSG positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $99.8K. The largest seller was Millennium Management, exiting entirely with an estimated $45K sold.
- 11 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q4 2013, up from 10 in Q3 2013.
- Funds reported $476K of Rosetta Genomics Ltd. stock for Q4 2013, up 51% quarter-over-quarter.
- 4 funds opened new Rosetta Genomics Ltd. positions in Q4 2013 and 3 closed out, a net change of +1 holder.
- The largest Rosetta Genomics Ltd. buyer in Q4 2013 was Tower Research Capital (TRC), an estimated $99.8K added.
- The largest Rosetta Genomics Ltd. seller in Q4 2013 was Millennium Management, an estimated $45K sold.
Based on aggregated 13F filings for Q4 2013.